DUPILUMAB IMPROVES LUNG FUNCTION ACROSS BASELINE DISEASE CHARACTERISTICS IN PATIENTS WITH EVIDENCE OF TYPE 2 INFLAMMATION AT BASELINE: THE LIBERTY ASTHMA QUEST STUDY

Abstract

Dupilumab, a fully human VelocImmune®-derived monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/IL-13, key drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), add-on dupilumab 200 mg/300 mg every 2 weeks (q2w) vs placebo reduced severe exacerbations and improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) in patients with uncontrolled, moderate-to-severe asthma. Treatment effects were greater in patients with elevated type 2 biomarkers at baseline. This post hoc analysis assessed the effects of dupilumab on pre-bronchodilator FEV1 by baseline disease characteristics in patients with ba..